NYMOX Pharmaceutical (NASDAQ: NYMX} rather surprisingly announced today that despite previous setbacks, they are continuing with the phase 3 trial from their prostrate enlargement drug NX-1207.
CEO Paul Averback commented that management are “still confident that NX-1207 has long term potential in the treatment of BPH”.